Our publications

Building the foundation for tomorrow’s medicines

In 2006, BioNTech’s co-founders, Ugur Sahin and Özlem Türeci, published their first peer-reviewed paper in the journal Blood: “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.” This marked a pivotal moment in their systematic efforts to address key scientific challenges such as improving the stability and efficacy of RNA, which began in the late 1990s.

The 2006 publication was just the beginning. Since then, BioNTech’s co-founders, along with their teams, have published numerous scientific papers spanning various therapeutic modalities. These publications reflect their unwavering vision to translate science into survival by developing innovative therapies and vaccines aimed at improving the health of people worldwide. From foundational discoveries to cutting-edge advancements, BioNTech’s research continues to push the boundaries of medical science, driving progress toward improving or establishing new standards of care.

mRNA based immunotherapies

Lang F et al.
Identification of neoantigens for individualized therapeutic cancer vaccines
Science Translational Medicine (2021)

Beck JD et al.
mRNA therapeutics in cancer immunotherapy
Molecular Cancer (2021)

Vormehr M et al.
Personalized Neo-Epitope Vaccines for Cancer Treatment
Current Immunotherapeutic Strategies in Cancer (2019)

Pastor F et al.
An RNA toolbox for cancer immunotherapy
Nature Reviews Drug Discovery (2018)

Shraibman B, Barnea E et al.
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma
Molecular and Cellular Proteomics (2018)

Rosigkeit S et al.
Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice
Molecular Pharmaceutics (2018)

Sahin U, Türeci Ö.
Personalized vaccines for cancer immunotherapy
Science (2018)

Türeci Ö et al.
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Clinical Cancer Research (2016)

Vormehr M et al.
Mutanome directed cancer immunotherapy
Current Opinion in Immunology (2016)

Vormehr M et al.
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Journal of Immunology Research (2015)

Sahin U, Karikó K, Türeci Ö.
mRNA-based therapeutics--developing a new class of drugs
Nature Reviews Drug Discovery (2014)

Show more
Show less

Next-generation immunomodulators

Targeted therapies

Explore more